A DVT or PE diagnosis requires immediate anticoagulation and a clear plan for the months ahead. This guide covers the medical aid steps from hospital to long-term management.
The Honest Starting Point
Acute DVT/PE treatment is PMB-covered. Your main ongoing financial decision is the anticoagulation choice: warfarin (cheap, requires monitoring) or a DOAC (expensive, convenient). Getting the DOAC on your scheme's formulary — or negotiating formulary access — is the key step for many patients.
Step 1: In-Hospital — Get the Acute Phase Right
During the acute admission: 1. Confirm your admission is pre-authorised. In an emergency, this happens retrospectively — your scheme must accept the PMB admission. 2. Your treating specialist (haematologist, physician, or pulmonologist) will initiate anticoagulation — typically a DOAC (rivaroxaban or apixaban) or injectable heparin bridging to warfarin. 3. Before discharge, confirm: - Which anticoagulant you are being discharged on - Duration of treatment (3 months? 6 months? Indefinite? Reassess date?) - Whether thrombophilia testing is indicated (for unprovoked events) - Follow-up appointment timeline
- Notify your gap cover provider within 24–48 hours if not already done.
Step 2: Confirm DOAC Formulary Access
If your specialist has prescribed a DOAC (rivaroxaban, apixaban, dabigatran), confirm scheme coverage before you pay for the first dispensing:
Call your scheme: "I have been prescribed [rivaroxaban/apixaban] for acute DVT/PE. Is this on my formulary? Is it covered under my acute or chronic medication benefit? What do I need to provide for approval?"
If it's on formulary: Get the chronic medication registration in place for 3-month supply dispensing.
If it requires a step-therapy: Your scheme may require warfarin first and DOAC only if warfarin is contraindicated or poorly controlled. Your haematologist/physician can submit a clinical motivation if DOAC is medically preferable for your case.
If cost is the constraint: Discuss with your doctor whether warfarin + INR monitoring is appropriate for your profile. For a 3-month provoked DVT with no recurrence risk, warfarin is clinically equivalent and dramatically cheaper.
Step 3: Set Up INR Monitoring (If on Warfarin)
If you are on warfarin, INR monitoring is non-negotiable — it determines whether your dose is in the therapeutic range (INR 2–3 for most VTE). Outside this range, you are either under-anticoagulated (clot risk) or over-anticoagulated (bleeding risk).
INR monitoring logistics: - Monthly pathology (more frequent when first starting or when dose changes) - Results to your GP or anticoagulation clinic - Warfarin dose adjusted based on result
Cost: INR blood test R80–R200 per test at a pathology lab. Funded from your pathology benefit.
Anticoagulation clinic option: Some hospitals and GP practices run anticoagulation clinics with point-of-care INR machines. This is more convenient but may cost more per visit than a standard pathology lab test.
Step 4: Investigate the Cause — Thrombophilia Testing
For unprovoked DVT/PE (no identifiable trigger like surgery, immobility, or pregnancy), thrombophilia testing is indicated to guide long-term anticoagulation decisions.
Testing typically includes: - Factor V Leiden mutation (most common hereditary thrombophilia in SA's mixed-race populations) - Prothrombin gene mutation - Protein C and S deficiency - Antithrombin III deficiency - Antiphospholipid antibodies (particularly relevant in SLE and HIV patients)
These tests are funded from your pathology benefit. Timing matters: some tests (protein C/S) should not be done while on anticoagulation — your haematologist will advise on timing.
A positive thrombophilia screen may mean indefinite anticoagulation is recommended, significantly changing your long-term cost and medication planning.
Step 5: Plan Long-Term Management
After the acute phase:
3-month follow-up: - Haematologist/physician review: day-to-day benefit - Reassess anticoagulation duration based on: VTE recurrence risk, thrombophilia result, patient preference, bleeding risk - Repeat imaging if post-thrombotic syndrome developing (leg pain, swelling persisting after DVT)
Post-thrombotic syndrome (PTS) prevention: - Graduated compression stockings (Class II — 23–32mmHg) are recommended for 2 years after DVT to reduce PTS risk - Stockings cost R400–R1,200 per pair; are OOP (not typically covered) - Consider a prescription for compression stockings from your vascular surgeon or physician — some schemes fund one pair per year under a medical item benefit
Indefinite anticoagulation planning: - If indefinite DOAC is recommended, consider your annual budget: R7,200–R14,400/year - Ensure your plan has sufficient MSA or ATB to sustain this without depleting your benefit - Annual specialist review to reassess the continued need for anticoagulation
Travel After DVT/PE
You may return to flying after a DVT or PE once anticoagulation is established (usually after 4–6 weeks for stable patients). Before long-haul travel: - Discuss with your haematologist or physician - Wear compression stockings on the flight - Stay hydrated; walk and exercise legs during the flight - Consider a "booster dose" of anticoagulant for very long flights (discuss with your doctor)
Travel insurance: if you have an active VTE diagnosis, ensure your travel insurance covers the condition. Standard travel insurance policies may exclude pre-existing conditions — check the policy wording.
Support Resources
South African Haematology Association (SAHA): saha.org.za Council for Medical Schemes: 0861 123 267 | www.medicalschemes.co.za
Talk to Eldon
Long-term anticoagulation is a sustained day-to-day cost. AURA helps identify plans with strong medication benefits and ATB structures that accommodate DOAC costs without depleting your MSA.
Review your plan for DVT/PE management →